InvestorsHub Logo

MayoMobile

07/13/21 7:07 PM

#320933 RE: boi568 #320932

I have tried to find Misslings source for 90% S1R WT prevalence a few times now and just can’t find it. I am assuming he is seeing that to be the case in our trials or he got the number from newly published reporting. In any case 84% + impressive.

I got my stat from a large independent genomic study.

frrol

07/13/21 7:51 PM

#320936 RE: boi568 #320932

How may chickens is that?

AD is a huge potential market. With a successful P2/3, we'll be a lot closer. Watch for trial results. We don't have a magic bean.

Bourbon_on_my_cornflakes

07/13/21 8:09 PM

#320939 RE: boi568 #320932

WHAT THE HECK: Bourbon's buyout number looks better and better, if not his strategy.

What does that throwaway line mean?


If you know my "strategy", you know I am hoping eventually for a 4 digit price, stock splits and massive dividends of an independent Anavex BP.

...but if people talk about buyouts, well then the price better be very HIGH.

bas2020

07/14/21 8:49 AM

#320991 RE: boi568 #320932

Blarcamesine will be prescribed to ALL AD patients. There will likely be some therapeutic benefit to even the least responsive. And why not when it's safe to take?